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There are numerous methodologies available for the analysis of genomic CFTR DNA. We present here the basic tools to allow a thorough
investigation of the CFTR gene, beginning with the identification of potential regulatory regions using DNase I hypersensitive sites, and
continuing with methods for the detection of mutations: denaturing High Performance Liquid Chromatography (dHPLC), Single Strand
Conformation Polymorphism (SSCP), and allele-specific oligonucleotide (ASO) hybridisation. Also provided is a comprehensive set of PCR
primers for the amplification of most regions of the CFTR gene. Full details of the methodologies given are to be found at the European
Working Group on CFTR Expression website http://central.igc.gulbenkian.pt/cftr/vr/transcripts.html.
D 2004 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: CFTR; Mutation detection; DNase I; dHPLC; SSCP; ASO1. Introduction
There are numerous methodologies at the disposal of
the molecular geneticist for the analysis of genomic CFTR
DNA. We present here the basic tools to allow a thorough
investigation of the CFTR gene and the development of a
strategy for the identification of all sequence changes in
the CFTR gene. Beginning with the identification of
potential regulatory regions using DNase I hypersensitive
sites, we then describe three different protocols for the
detection of mutations: denaturing High Performance
Liquid Chromatography (dHPLC), Single Strand Confor-1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2004.05.003
Abbreviations: ASO, allele-specific oligonucleotide; DGGE, denaturing
gradient gel electrophoresis; dHPLC, denaturing High Performance Liquid
Chromatography; HD heteroduplex (NP-40), Nonidet P-40; PBS, phos-
phate buffered saline; PMSF, phenyl methyl sulfonyl fluoride; SSCP, Single
Strand Conformation Polymorphism.
* Corresponding author. Tel.: +44-161-727-2567; fax: +44-161-727-
2328.
E-mail address: Martin.Schwarz@CMMC.nhs.uk (M.J. Schwarz).mation Polymorphism (SSCP), and allele-specific oligo-
nucleotide (ASO) hybridisation. Also provided is a
comprehensive set of PCR primers that can be used for
the amplification of most regions of the CFTR gene. Full
details of the methodologies given are to be found in the
found at the European Working Group on CFTR Expres-
sion website [1].2. Identification of potential regulatory elements
2.1. Assay for DNase I hypersensitive sites in chromatin
This protocol describes the extraction of chromatin from
tissues and cells to subsequently map and evaluate DNase
I hypersensitive sites that are often associated with regu-
latory elements in a gene. The method of extraction of
chromatin from tissues is adapted from Becker et al. [2].
The extraction of chromatin from cells was adapted from
Higgs et al. [3]. The whole procedure has to be performed
at 4 jC. Tissue is roughly mashed and added to buffer Aed by Elsevier B.V. All rights reserved.
1 The author (M. Schwarz) will be pleased to respond to requests for
further information.
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EGTA; 2 EDTA; 0.5 spermidine; 0.15 spermine; 0.5 h-
mercaptoethanol; 5 DTT; 1 phenyl methyl sulfonyl fluo-
ride, PMSF (10 ml/g of tissue). Spermidine, spermine, h-
mercaptoethanol, DTT and PMSF are added just before
use. The tissue is then homogenized and filtered 2
through sterile gauzes. The volume is then adjusted to
50 ml with buffer A and the suspension is centrifuged at
3000 g for 10 min at 4 jC. The pellet is resuspended in
5 ml of buffer A and the cells lysed by adding 5 ml of
buffer A containing 0.8% (v/v) triton X100. The resulting
suspension is then mixed and incubated on ice for 10 min.
This is then centrifuged at 3000 g for 15 min at 4 jC
and the resultant pellet resuspended in 10 ml of buffer A.
This wash is repeated three times, before filtering through
a 70 Am cell strainer. The product is then centrifuged at
1000 g for 10 min at 4 jC, and the pellet resuspended in
50 ml of RBS (mM): 10 Tris HCl pH 7.5; 10 NaCl; 3
MgCl2. This is then centrifuged at 1000 g for 10 min at
4 jC and the pellet resuspended in 0.8 ml of RSB, before
proceeding to DNase I digestion of samples.
To extract chromatin from cells, 108 cells are trypsi-
nised or harvested for suspension cultures; the cells are
washed twice with phosphate-buffered saline, PBS (0.02%
(w/v) KCl; 0.02% (w/v) KH2PO4; 0.8% (w/v) NaCl;
0.115% (w/v) Na2HPO4 pH7.4), centrifuged at 200 g
for 5 min at 4 jC and resuspended in 50 ml of PBS.
After three washes the cell pellet is resuspended in 20 ml
PBS. Cells are lysed and nuclei released by adding 20 ml
of RSB containing 0.2% (v/v) Nonidet P-40 (NP-40).
After 10 min on ice, the cells are centrifuged at 200 g
for 5 min at 4 jC and the nuclei resuspended in 50 ml of
RSB. The nuclei are then centrifuged at 200 g for 5
min at 4 jC and resuspended in 1 ml of RSB. 200 Al of
nuclei suspension is aliquoted into six tubes containing
800 Al of RSB.
DNase I (Amersham Pharmacia, Little Chalfont, UK,
cat no.: 27-0514-02) is used for digestion. One tube with
no DNase I remains at 4 jC, and a second tube with no
DNase I is incubated at 37 jC as a control for any
endogenous DNase I activity. The remaining four tubes
that contain increasing amount of DNase I are incubated at
37 jC (about 20 min) until the penultimate tube is clear
(not viscous) when mixed with 50 Al of lysis buffer (10
mM Tris HCl pH 8.0; 10 mM NaCl; 10 mM EDTA pH 8;
0.5% (w/v) SDS). 1 ml of lysis buffer is added to the
remaining samples to stop the reaction. DNase I digestion
may also be carried out with the same amount of enzyme
in each tube but increasing incubation times. 10 Al of
proteinase K (50 mg/ml) is added to each sample and
incubated at 37 jC overnight. If the DNA solution is still
viscous, more proteinase K is added and incubated until
the solution is no longer viscous. After one phenol/chlo-
roform extraction and two chloroform extractions, the
samples are precipitated in two volumes of ethanol
(100%) plus 1/10 volume of 5 M NaCl. This is incubatedat  20 jC for 2 h, after which it is centrifuged at
2000 g for 30 min at 4 jC. The pellet is then air-dried
and resuspended in 200 Al of TE (10 mM Tris; 0.1 mM
EDTA; pH 8.0), before storage at  20 jC.3. Detection of mutations in the CFTR gene
3.1. Amplification of CFTR exons and coding regions
Numerous PCR primers have been described for am-
plification of the CFTR gene. A comprehensive list of
tried and tested primers currently in use can be found in a
‘Table of Primers for CFTR gene Amplification’ at the
European Working Group on CFTR Expression website
[1]. Whilst it is relatively easy to design primers to
amplify a particular exon, some thought must be given
to the application the PCR products are intended for.
Some of the primers can be used for more than one
application (e.g. sequencing, single-stranded conforma-
tional polymorphism, SSCP, etc.) but others are restricted
to a specific purpose.
3.1.1. Notes to ‘Table of Primers for CFTR gene
Amplification’ [1]1
1. Primers named (exon)i5 and (exon)i3 are those suggested
by Zielenski et al. [4]. These generally give a PCR
product of 400–500 bases and may be used for general
screening of the relevant exon.
2. Primers with the prefix ‘DCF’ are derived from Fanen et
al. [5] and are the primers for denaturing gradient gel
electrophoresis (DGGE) from that paper, less the GC-
clamp. These primers generally give a PCR product of a
size more useful for SSCP and sequencing than the
Zielenski primers [4].
3. Primers containing the letters ‘sp’ have been designed
especially for sequencing and are not usually used in a
pair.
3.2. Mutation detection of CFTR gene by HPLC
Denaturing High Performance Liquid Chromatography
(dHPLC) has been described in the past years as a method
of scanning DNA samples for point mutations or variations
in the genome. Initially, HPLC was a tool to separate DNA
fragments as small oligonucleotides, PCR fragments, etc.
The development of columns containing alkylated non-
porous particles has opened a new approach to research
development in the field of mutation/polymorphism detec-
tion. This technique involves subjecting PCR products to
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containing alkylated non-porous particles.
Within a linear acetonitrile gradient and under partial
heat denaturation, heteroduplexes (HDs) that may be present
in a PCR product display a reduced column retention time
compared with their counterpart wild-type (wt) homodu-
plexes. The pattern of profile of these HDs is in the majority
of cases easily detected and additional techniques are used
(such as sequencing) to confirm the presence of a mutation
or sequence variation.
The list of genes studied by dHPLC as at October
2003 is available elsewhere [6]. More than 250 genes
responsible for human diseases have now been totally or
partially analysed by dHPLC and this technique is be-
coming one of the most popular for mutation scanning.
The dHPLC technique has been compared to other
methods with regard to sensitivity, cost and time taken
to obtain the results. The conclusion of most of these
studies was that dHPLC is effective, fast and sensitive for
the detection of point mutations and polymorphisms. This
is also our conclusion after having designed primers to
enable complete scanning of the 27 exons of the CFTR
gene by dHPLC. For this reason, we believe dHPLC is
now the ‘Gold Standard’ for analysing the CFTR gene,
which is one of the most highly mutated genes in the
human genome.
3.3. CFTR gene analysis by SSCP
3.3.1. General strategy of the assay
The large size of many disease genes and the multi-
plicity of mutations complicate the design of an adequate
assay for the identification of disease causing sequence
variants. In the past 10 years, SSCP and HD analysis have
rapidly gained popularity as two of the most straightfor-
ward and versatile methods to screen for DNA alterations
[7]. The principle reasons for the popularity of these two
methods are their technical simplicity and their high
sensitivity for the detection of mutations. Traditionally,
SSCP and HD are prepared separately involving time-
consuming (12–14 h), labour-intensive, and cumbersome
electrophoresis of radioactively labelled DNA samples
under non-denaturing conditions in a high resolving
cross-linked polyacrylamide gel and affording relatively
low sensitivity of mutation detection (60–90%) [7]. To
increase sensitivity and specificity of SSCP and HD
analysis, several factors have to be optimised. For SSCP
analysis, these factors include: choice of gel matrix,
electrophoretic conditions, presence of neutral additives,
fragment size, and G +C content. For HD analysis, the
principle factors influencing sensitivity are the gel matrix
and the identity of the base mismatch. Thus varying these
parameters, we optimised the sensitivity of our combined
SSCP/HD protocol, simultaneously performing SSCP and
HD analysis on the same gel and therefore increasing the
sensitivity of both methods [8]. We defined uniform SSCP/HD conditions, such as 12% (w/v) non-denaturing poly-
acrylamide gel, 7% (v/v) glycerol, two-phase buffer sys-
tem, 90 min electrophoresis at 12–15 jC, and silver
staining. These conditions can be used for mutation
screening in all 27 CFTR exons, or in any other genes.
Additionally, restriction enzyme digest of the amplification
product of each CFTR exon further increases mutation
detection.
3.3.2. Screening strategy and mutation detection rate
We present a three-step screening strategy allowing
analysis of the sequences with first priority within 5
h and analysis of the entire coding and adjacent noncoding
regions within 1 week, including sequence analysis of the
variants. The screening strategy is based on the abundance
of mutations in the CFTR gene [8]. The first priority
includes: exon 3, 4, 7, 10, 11, 13, 17b, 19, 20, 21 and
intron 19. The second priority: exon 2, 5, 6a, 12, 14b, 15,
16, 17 and intron 11. The third priority: exon 1, 6b, 8, 9,
14a, 18, 22, 23, 24 and the promoter sequence. Many of
the fragments are longer than 300 bp, but this does not
seem to be a disadvantage in identifying point mutations.
The reason why particular mutations can only be identified
with, or without, digestion of the PCR product may be
based on the fact that digestion alters the position of the
sequence variant within the amplification product and in
consequence also the conformation of the single-strand
and/or the HD formation allowing or preventing the
detection of a band shift. In our initial study, a total of
80 known CF mutations (28 missense, 22 frameshift, 17
nonsense, 13 splicesite) and 20 polymorphisms was ana-
lysed resulting in a detection rate of 97.5% including the
24 most common mutations worldwide [8]. More recently,
the protocol proved to be able to detect mutations inde-
pendent of their nature, frequency, and population speci-
ficity, which is also confirmed by the identification of
novel mutations (i.e. 420del9, 1199delG, R560S, A613T,
T1299I) in Swiss CF patients. 93 different mutations have
been detected in 1200 patients analysed so far. This
protocol represents a general model for point mutation
analysis in genetic disorders and is successfully used for
the analysis of a number of disease-causing genes. In
conclusion, this protocol provides firm evidence that this
SSCP/HD technique is very fast and has the ability to
detect at least 97% of all sequence variants in the coding
region of the CFTR gene. Thus, we consider it to be a
high-yield scanning method that can be recommended to
laboratories involved in the mutation screening of geneti-
cally heterogeneous populations.4. Detection of F508del by ASO hybridization
The complete protocol can be used to screen for known
mutations in CFTR DNA, either in genomic DNA (from
patients, carriers) or in plasmids (e.g. to screen for mutants
C. Fe´rec et al. / Journal of Cystic Fibrosis 3 (2004) 7–1010after a mutagenesis protocol). It can be found online at the
European Working Group on CFTR Expression website [1].
Two oligonucleotide probes (one complementary to the
mutant sequence and another to the wt sequence in the same
DNA region) should be used. Samples (PCR amplicons or
plasmids) that fail to hybridize with one probe should
hybridize positively with the other probe. Exceptions are
amplicons from individuals who are heterozygous for the
mutation under analysis. For these, positive signals (though
weaker) should be seen with both probes. When a mixture
of plasmids (wt and mutant) is present a similar result is
obtained.
Positive controls for each sequence (acting as negative
controls for the other) should always be included on the
same filter as samples.
4.1. Protocol outline
After soaking the membrane first in distilled water and
then into 2 SSC, it is assembled into the appropriate dot-
blot apparatus [1]. Following denaturing in appropriate
solution, DNA samples under test are then applied on the
membrane with the help of the three-valve system that
regulates vacuum flow. Samples on apparatus wells are
washed with 2 SSC (with vacuum off). The vacuum is
turned on again and after solution absorption, the apparatus
is disassembled, the membrane soaked into 2 SSC and
air-dried, before incubation at 80 jC for 2 h for DNA
fixation.
Stringent hybridization with oligonucleotidic probes2
(radiolabelled with [g-32P]dATP by T4 polynucleotide
kinase) is carried out at 50 jC for 2 h, after overnight
pre-hybridization at the same temperature. The hybridized
membrane is then washed under stringent conditions
(including two 30-min washes at a higher temperature)
to remove unspecifically bound probe and air-dried. Be-2 Sequence of probes for F508del detection is available elsewhere [1].fore exposure to an X-ray film, with intensifying screens
for 2 h at  80 jC.Acknowledgements
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